ST. LOUIS, MO--(Marketwired - Nov 21, 2013) - Murphy Analytics (MA) has initiated coverage on Arrayit Corporation (
Arrayit utilizes its patented and proprietary microarray platform to lead and empower the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.
Analyst Patrick Murphy notes in the report: "As discussed in more detail later in the report, the trend towards personalized medicine in which analysis and treatment is customized to a patient's molecular and genetic profile is creating vast market opportunities... As a pioneer in microarray technology, ARYC helped to develop the industry."
About Murphy Analytics
Murphy Analytics is an independent investment research firm providing coverage of microcap stocks. Utilizing institutional caliber, fundamental analysis, Murphy Analytics helps readers become more informed about equities without extensive analyst coverage. Murphy Analytics LLC is owned by Patrick J. Murphy, who has nearly 20 years of capital markets experience, providing institutional investment and transaction analysis across a range of asset classes including microcap equities, commercial real estate debt and equity, municipal derivatives and public finance, venture capital, fixed income, CMBS and mortgage REIT's.
Disclosure: MA was paid $5,000 by an ARYC investor in advance of the publication of this report. Neither MA nor the analyst owns or trades the shares of covered companies. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. MA provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. This report is neither a solicitation to buy nor an offer to sell securities and is to be used for informational purposes only and should not be used as basis for investment decisions. MA is not an investment advisor or broker/dealer and this report does not provide investment advice.